Department of Surgery, Henry Ford Health System, Detroit, MI 48109, USA.
Ann Surg. 2013 May;257(5):791-7. doi: 10.1097/SLA.0b013e3182879ded.
To evaluate the comparative effectiveness of sleeve gastrectomy (SG), laparoscopic gastric bypass (RYGB), and laparoscopic adjustable gastric banding (LAGB) procedures.
Citing limitations of published studies, payers have been reluctant to provide routine coverage for SG for the treatment of morbid obesity.
Using data from an externally audited, statewide clinical registry, we matched 2949 SG patients with equal numbers of RYGB and LAGB patients on 23 baseline characteristics. Outcomes assessed included complications occurring within 30 days, and weight loss, quality of life, and comorbidity remission at 1, 2, and 3 years after bariatric surgery.
Matching resulted in cohorts of SG, RYGB, and LAGB patients that were well balanced on baseline characteristics. Overall complication rates among patients undergoing SG (6.3%) were significantly lower than for RYGB (10.0%, P < 0.0001) but higher than for LAGB (2.4%, P < 0.0001). Serious complication rates were similar for SG (2.4%) and RYGB (2.5%, P = 0.736) but higher than for LAGB (1.0%, P < 0.0001). Excess body weight loss at 1 year was 13% lower for SG (60%) than for RYGB (69%, P < 0.0001), but was 77% higher for SG than for LAGB (34%, P < 0.0001). SG was similarly closer to RYGB than LAGB with regard to remission of obesity-related comorbidities.
With better weight loss than LAGB and lower complication rates than RYGB, SG is a reasonable choice for the treatment of morbid obesity and should be covered by both public and private payers.
评估袖状胃切除术(SG)、腹腔镜胃旁路术(RYGB)和腹腔镜可调节胃束带术(LAGB)的疗效。
由于发表的研究存在局限性,支付方一直不愿意为治疗病态肥胖症提供 SG 的常规报销。
我们使用外部审核的全州临床注册数据,根据 23 项基线特征,将 2949 例 SG 患者与 RYGB 和 LAGB 患者进行匹配,各有 2949 例。评估的结果包括术后 30 天内发生的并发症,以及减肥手术 1、2 和 3 年后的生活质量和合并症缓解情况。
匹配后的 SG、RYGB 和 LAGB 患者在基线特征上具有良好的平衡性。SG 患者(6.3%)的总体并发症发生率明显低于 RYGB(10.0%,P < 0.0001),但高于 LAGB(2.4%,P < 0.0001)。SG(2.4%)和 RYGB(2.5%)的严重并发症发生率相似(P = 0.736),但高于 LAGB(1.0%,P < 0.0001)。SG 患者术后 1 年时多余体重减轻率(60%)比 RYGB(69%)低 13%(P < 0.0001),但比 LAGB(34%)高 77%(P < 0.0001)。SG 在缓解肥胖相关合并症方面也比 LAGB 更接近 RYGB。
SG 的减重效果优于 LAGB,并发症发生率低于 RYGB,因此是治疗病态肥胖症的合理选择,应得到公共和私人支付方的覆盖。